InStride Health

Overview

InStride Health is a specialty pediatric behavioral health provider that focuses on treating anxiety and obsessive-compulsive disorder (OCD) in children, teens, and young adults. The company was founded in 2021 by Dr. Mona Potter, Dr. Kathryn Boger, John Voith, and James McElhiney, leveraging their expertise from McLean Hospital, a leading psychiatric hospital. Based in Boston, Massachusetts, InStride Health has raised a total of $56 million across several funding rounds. The company offers an innovative, evidence-based model of care that is predominantly virtual and covered by major insurance plans.

Recent Developments

July 2024: InStride Health secured $30 million in Series B funding. This investment, led by General Catalyst with participation from .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation, was aimed at expanding market reach and enhancing clinical quality. This new round of funding increased the company’s total raise to $56 million.
March 2024: Building upon their partnership with McLean Hospital, InStride Health continued to expand its healthcare services into new states, planning coverage in Maine and enhancing virtual treatment accessibility for pediatric anxiety and OCD.
September 2023: Released its first outcomes report showing significant clinical results: 90% of program graduates reported reduced anxiety after two months of treatment, and 82% saw a decrease in functional impairment and symptom severity within three months. The expansion also covers more insurance plans to include underserved populations.
2023-2024: The company emphasized the integration of a holistic and accessible care model by accepting major insurance plans across several states, which has enhanced its service delivery to underserved populations, including rural areas.
Early 2023: InStride Health saw a strategic expansion in its service offering and geographic presence, allowing it to cover multiple states in the Northeastern United States and ensuring insurance coverage arrangements that facilitate affordable care access.

Attribute	Information
Founding Date	2021
Headquarters	Boston, Massachusetts, United States
Founders	Dr. Mona Potter, Dr. Kathryn Boger, John Voith, James McElhiney
Revenue	Not publicly disclosed
Profits	Not publicly disclosed
Key Investors	General Catalyst, .406 Ventures, Mass General Brigham Ventures, Hopelab Foundation
Industry	Pediatric Mental Health Care
Number of Employees	Approximately 158

Early History

InStride Health was founded in 2021 by a team of healthcare professionals with extensive experience in pediatric mental health. The co-founders, Dr. Mona Potter and Dr. Kathryn Boger, utilized their knowledge and expertise gained from their tenure at McLean Hospital, America's top-rated psychiatric institution. They aimed to address the growing mental health crisis among the youth by democratizing access to high-quality, evidence-based treatment for anxiety and OCD. The initial growth of the company was marked by a successful Series A funding round which raised $26 million, enabling the expansion of its virtual care model across various states.

Company Profile and Achievements

InStride Health operates a unique clinical model integrating a multidisciplinary approach in treating anxiety and OCD in children, teens, and young adults between the ages of 7-22.
The care model includes cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and components of dialectical behavior therapy (DBT), focusing heavily on exposure and response prevention (ERP).
InStride has a data-driven approach with Measurement-Based Care (MBC) allowing for real-time monitoring of treatment progress and adjustments.
The company has expanded its reach significantly, providing treatment services in eight states and planning further geographic expansions.
In terms of achievements, 90% of its patients report a reduction in anxiety symptoms within two months of treatment.

Current Operations and Market Position

InStride Health's current operations are focused on providing virtual mental health services, facilitating access to underserved regions, and expanding its service range to new states. The company’s operations are underpinned by strategic partnerships with insurance providers, which allow coverage for a majority of patients, reducing care costs significantly. The approach has positioned InStride as a leading provider in pediatric mental health, known for its efficient integration of technology with traditional therapy methods.

Conclusion

InStride Health has rapidly emerged as an influential force in pediatric mental healthcare, owing to its innovative approach that combines evidence-based treatments with digital technology. Secure funding and strategic market expansion efforts attest to the scalability and demand for their services. Looking forward, InStride Health is poised to further revolutionize anxiety and OCD treatment for children and teens, continuing to lower barriers to access while enhancing clinical outcomes.